Controlled release hydrophilic matrix tablet formulations of isoniazid: design and in vitro studies.
The aim of the present investigation was to develop oral controlled release matrix tablet formulations of isoniazid using hydroxypropyl methylcellulose (HPMC) as a hydrophilic release retardant polymer and to study the influence of various formulation factors like proportion of the polymer, polymer viscosity grade, compression force, and release media on the in vitro release characteristics of the drug. The formulations were developed using wet granulation technology. The in vitro release studies were performed using US Pharmacopoeia type 1 apparatus (basket method) in 900 ml of pH 7.4 phosphate buffer at 100 rpm. The release kinetics was analyzed using Korsmeyer-Peppas model. The release profiles were also analyzed using statistical method (one-way analysis of variance) and f (2) metric values. The release profiles found to follow Higuchi's square root kinetics model irrespective of the polymer ratio and the viscosity grade used. The results in the present investigation confirm that the release rate of the drug from the HPMC matrices is highly influenced by the drug/HPMC ratio and viscosity grade of the HPMC. Also, the effect of compression force and release media was found to be significant on the release profiles of isoniazid from HPMC matrix tablets. The release mechanism was found to be anomalous non-Fickian diffusion in all the cases. In the present investigation, a series of controlled release formulations of isoniazid were developed with different release rates and duration so that these formulations could further be assessed from the in vivo bioavailability studies. The formulations were found to be stable and reproducible.
Hiremath
Praveen S
PS
Pharmacy Group, Birla Institute of Technology and Science, Pilani, Rajasthan, India. phiremath@pharm-int.com
Saha
Ranendra N
RN
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations; D006207:Half-Life; D066298:In Vitro Techniques; D007538:Isoniazid / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet; D013607:Tablets
D000995:Antitubercular Agents; D003692:Delayed-Action Preparations; D013607:Tablets; D007538:Isoniazid